SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art-Reference-Cited by-同舟云学术

SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art

Published:2024-08-24 Issue: Volume: Page:
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Aristizábal-Colorado David^ORCID,Ocampo-Posada Martín^ORCID,Rivera-Martínez Wilfredo Antonio^ORCID,Corredor-Rengifo David^ORCID,Rico-Fontalvo Jorge^ORCID,Gómez-Mesa Juan Esteban^ORCID,Duque-Ossman John Jairo^ORCID,Abreu-Lomba Alin^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40256-024-00673-1.pdf

Reference100 articles.

1. Liu L, Simon B, Shi J, Mallhi AK, Eisen HJ. Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: Evidence on health outcomes and antidiabetic treatment in United States adults. World J Diabetes. 2016;7:449–61. https://doi.org/10.4239/wjd.v7.i18.449.

2. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis Off J Natl Kidney Found. 2012;60:850–86. https://doi.org/10.1053/j.ajkd.2012.07.005.

3. Wu B, Bell K, Stanford A, Kern DM, Tunceli O, Vupputuri S, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012. BMJ Open Diabetes Res Care. 2016;4: e000154. https://doi.org/10.1136/bmjdrc-2015-000154.

4. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22. https://doi.org/10.1056/NEJMoa1603827.

5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720.